CRISPR Therapeutics's Options Frenzy: What You Need to Know

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried?

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025--Phase 1 ...

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its ...
STAT

At AHA meeting, CRISPR data gleamed but ‘food as medicine’ spoke to the now

A record-breaking 4,432 scientific abstracts accepted at the American Heart Association’s meeting here adorned posters, ...
BioSpace

Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...
Fierce Biotech

Patient dies after receiving Intellia's CRISPR therapy

The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...